Evidence map›Paper›PMID 33167721›Full record

ArticleLeukemia & lymphoma2020

SARS-CoV-2 in multiple myeloma: initial observation and management.

Elisabet E Manasanch, Victor Mulanovich, Joanna-Grace Manzano, Maria Susan Gaeta, Melody Becnel, Gregory P Kaufman, Hans C Lee, Behrang Amini, Sheeba K Thomas, Swaminathan P Iyer and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elisabet E ManasanchDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Victor MulanovichDepartment of Internal Medicine/Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joanna-Grace ManzanoDepartment of Internal Medicine/Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Susan GaetaDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melody BecnelDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gregory P KaufmanDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hans C LeeDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Behrang AminiRadiodiagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sheeba K ThomasDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Swaminathan P IyerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Donna M WeberDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zuzana BerkovaDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher R FlowersDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert Z OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krina K PatelDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2016 to 2020
$1.8M
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2015 to 2019
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA184464NCI NIH HHS R01 CA194264NCI NIH HHS U10 CA032102
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedBetacoronavirusCoronavirus InfectionsCOVID-19Disease ManagementFemaleHumansMaleMiddle AgedMultiple MyelomaPandemicsPneumonia, ViralPrognosisSARS-CoV-2

Identifiers

PMID33167721
PMCPMC8092112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.